Intestinal Behçet’s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis

Table 1 Clinical characteristics of patients with intestinal Behçet’s disease receiving infliximab or adalimumab

Case	Age (yr)/gender	Duration of disease (yr)	Anti TNF-αAb for induction	Previous therapies	Maintenance therapy	Outcomes	Follow-up duration after achieving remission	Ref.
1	32/F	5	IFX	Steroids	IFX	Remission	9 mo	[14]
				6-MP	6-MP
2	37/F	2	IFX	Mesalamine	IFX	Remission	16 mo	[14]
				Steroids	6-MP
				6-MP
3	51/M	4	IFX	Steroids	IFX	Remission	3 yr	[14]
				Methotrexate
4	38/M	5	IFX	Steroids	IFX	Remission	10 mo	[14]
				Colchicines
				Cyclosporine A
5	43/F	6	IFX	Steroids	AZA	Surgery	6 mo	[14]
				Azathioprine
6	38/M	3	IFX	Steroids	IFX	Remission	2 yr	[14]
				6-MP	6-MP
7	35/F	Over 20	IFX	Steroids	Methotrexate	Relapse	8 mo1	[7]
				Azathioprine
8	27 /F	2	IFX	Steroids	Steroids	Remission	17 mo	[5]
				Thalidomide	Thalidomide
9	30 /F	3	IFX	Steroids	Thalidomide	Relapse	10 mo1	[5]
				Colchicines
				Cyclosporine
10	42/M	11	IFX	Steroids	-	Remission	1 wk	[9]
				Colchicine
11	47/M	20	IFX	Sulfasalazine	-	Remission	12 mo	[4]
				Steroids
				Azathioprine
12	30/F	-	IFX	Steroids	IFX	Remission	22 mo	[10]
				Azathioprine	Switch to adalimumab
13	45/F	9	IFX	Mesalamine	IFX	Remission	25 wk	[6]
				Steroids
				6-MP

¹Duration between remission stage and the first relapse stage after infusion of anti tumor necrosis factor-α antibody (anti TNF-α Ab). F: Female; M: Male; IFX: Infliximab; 6-MP: 6-mercaptopurine.